about
The Extracellular Calcium-Sensing Receptor in the Intestine: Evidence for Regulation of Colonic Absorption, Secretion, Motility, and ImmunityCalcium-sensing receptor: A new target for therapy of diarrheaA gastrointestinal anti-infectious biotherapeutic agent: the heat-treated Lactobacillus LBHuman mini-guts: new insights into intestinal physiology and host-pathogen interactionsChemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging TreatmentsA high-sensitivity HPLC assay for measuring intracellular Na(+) and K(+) and its application to Plasmodium falciparum infected erythrocytesNanomolar-Potency Aminophenyl-1,3,5-triazine Activators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel for Prosecretory Therapy of Dry Eye Diseases.Drug-induced secretory diarrhea: A role for CFTR.CFTR activator increases intestinal fluid secretion and normalizes stool output in a mouse model of constipationPathophysiology of Intestinal Na+/H+ exchange.Targeting Small Bowel Receptors to Treat Constipation and Diarrhea.Inflammation-dependent cerebrospinal fluid hypersecretion by the choroid plexus epithelium in posthemorrhagic hydrocephalus.Fatty acid and mineral receptors as drug targets for gastrointestinal disorders.Small Intestinal Infections.Targeting and alteration of tight junctions by bacteria and their virulence factors such as Clostridium perfringens enterotoxin.The Zn2+-sensing receptor, ZnR/GPR39, upregulates colonocytic Cl- absorption, via basolateral KCC1, and reduces fluid loss.The Contributions of Human Mini-Intestines to the Study of Intestinal Physiology and Pathophysiology.Antidiarrheal Drug Therapy.Pro-Secretory Activity and Pharmacology in Rabbits of an Aminophenyl-1,3,5-Triazine CFTR Activator for Dry Eye DisordersCFTR-NHERF2-LPA₂ Complex in the Airway and Gut Epithelia.The Zinc Sensing Receptor, ZnR/GPR39, in Health and Disease.Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins.Intestinal electrolyte and fluid secretion: A model in trouble?Drug development and acute gastrointestinal infections.Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature.Enterohemorrhagic (EHEC)-Secreted Serine Protease EspP Stimulates Electrogenic Ion Transport in Human Colonoid Monolayers
P2860
Q26741598-A192F772-0140-4DD1-AC3B-4705405732B5Q26766058-33244A1B-6AFD-47C0-B150-AF16AA069FE1Q26771884-C6135C2B-DE94-48E3-A9EB-9684098368A6Q28066574-C074E4F3-0732-4C9B-899F-743D16E16422Q28079705-171B64A1-CF3E-4BA4-A716-30794268349BQ28831140-EFD9D0EE-EBC3-45F7-AC1B-03262FAC4459Q33752165-986289E8-7E11-41CE-9716-5A0A4F62F48EQ36385185-EB292A4A-CEE6-4F69-AAEC-E5761376F65DQ36833766-84FBF3F5-D80B-4674-A281-C16E72B75254Q37585753-70C57923-B278-4FD2-9F81-31578E97463DQ38673439-A7E5507B-59DF-4012-AD8F-3FC897C48A32Q38686602-0FC729A8-6B1D-4007-A8B3-1C7103ECB666Q38756670-1D9E62E6-EE1A-4D86-B0EB-9E1DB41A9B1DQ38832044-FDEFA45A-C722-49B1-8A03-DB24AEE5D5E8Q39013776-3E3D6B14-EA8B-4A2C-BEFA-ECA61D9CD2D4Q39017825-D057417F-B207-451A-AFF8-ACE2B4B20E72Q39133310-5934E8CD-AD83-4B05-ABB7-50888B1BF25BQ39233364-CA6D99BF-AD1C-4832-B5C7-B9A5EB91F6AFQ41615871-70D8AA10-5D90-4FFC-AF7E-EA9D08153475Q41660999-A670D9FE-37A5-4BD1-9493-5AFA6EADC995Q48124115-96EDC0DA-7F3E-4485-A03F-22318B8FF5B9Q51313072-3F0E482F-842B-4793-A81D-30C60616FDFEQ52804955-5F289C71-9B6C-492C-83E2-7AEA1A0D5231Q54298251-FC30E679-2D3E-4789-91A3-B5A12F3D4A4AQ55345479-8ED4AC4F-9E7E-48E1-99FE-BD4468758437Q58773623-5DFDB320-5ACE-44AA-8B2B-6508507F2A91
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Secretory diarrhoea: mechanisms and emerging therapies.
@ast
Secretory diarrhoea: mechanisms and emerging therapies.
@en
type
label
Secretory diarrhoea: mechanisms and emerging therapies.
@ast
Secretory diarrhoea: mechanisms and emerging therapies.
@en
prefLabel
Secretory diarrhoea: mechanisms and emerging therapies.
@ast
Secretory diarrhoea: mechanisms and emerging therapies.
@en
P2093
P2860
P1476
Secretory diarrhoea: mechanisms and emerging therapies.
@en
P2093
Alan S Verkman
Jay R Thiagarajah
Mark Donowitz
P2860
P2888
P304
P356
10.1038/NRGASTRO.2015.111
P407
P577
2015-06-30T00:00:00Z